Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1626-1634

  Amado, Rafael G ^a   Wolf, Michael ^b   Peeters, Marc ^b   Van Cutsem, Eric ^b   Siena, Salvatore ^b   Freeman, Daniel J ^b   Juan, Todd ^b   Sikorski, Robert ^b   Suggs, Sid ^b   Radinsky, Robert ^b   Patterson, Scott D ^b   Chang, David D ^b  

^a AMGEN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; K RAS PROTEIN; ONCOPROTEIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; RAS PROTEIN; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; AGED; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 42649145667     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.7116     Document Type: Article

References (38)

1. Shepherd FA, Rodrigues Pereira J, Cialeanu T, et al: Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 353:123-132, 2005
2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
3. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
4. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007
5. Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385, 2006
6. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 5:341-354, 2005
7. Adams R, Maughan T: Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Rev Anticancer Ther 7:503-518, 2007
8. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005
9. Mitchell EP, Hecht JR, Baranda J, et al: Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis. J Clin Oncol 25:184s, 2007 (suppl; abstr 4082)
10. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22, 2003
11. Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308, 2007
12. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
13. Malumbres M, Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer 3:459-465, 2003
14. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692-696, 2001
15. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007
16. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
17. Esteller M, Gonzalez S, Risques RA, et al: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299-304, 2001
18. Ince WL, Jubb AM, Holden SN, et al: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97:981-989, 2005
19. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006
20. Bazan V, Migliavacca M, Zanna I, et al: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13:1438-1446, 2002
21. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol [epub ahead of print on November 12, 2007]
22. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
23. Newton CR, Graham A, Heptinstall LE, et al: Analysis of any point mutation in DNA: The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516, 1989
24. Thelwell N, Millington S, Solinas A, et al: Mode of action and application of scorpion primers to mutation detection. Nucleic Acids Res 28:3752-3761, 2000
25. Whitcombe D, Theaker J, Guy SP, et al: Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 17:804-807, 1999
26. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
27. Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25:18s, 2007 (abstr 4509)
28. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896, 2007
29. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
30. Burmer GC, Loeb LA: Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci U S A 86:2403-2407, 1989
31. Hasegawa H, Ueda M, Watanabe M, et al: K-ras gene mutations in early colorectal cancer: Flat elevated vs polyp-forming cancer. Oncogene 10: 1413-1416, 1995
32. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
33. Nahta R, Yu D, Hung MC, et al: Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269-280, 2006
34. Lu Y, Li X, Liang K, et al: Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67:8240-8247, 2007
35. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
36. Sartore-Bianchi A, Moroni M, Veronese S, et al: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238-3245, 2007
37. Birchmeier C, Birchmeier W, Gherardi E, et al: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925, 2003
38. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518, 2004